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Abstract
Intense abdominal pain is a prominent feature of 
chronic pancreatitis and its treatment remains a major 
clinical challenge. Basic studies of pancreatic nerves 
and experimental human pain research have provided 
evidence that pain processing is abnormal in these 
patients and in many cases resembles that seen in 
neuropathic and chronic pain disorders. An important 
ultimate outcome of such aberrant pain processing is 
that once the disease has advanced and the patho-
physiological processes are firmly established, the 
generation of pain can become self-perpetuating and 
independent of the initial peripheral nociceptive drive. 
Consequently, the management of pain by traditional 
methods based on nociceptive deafferentation (e.g. , 
surgery and visceral nerve blockade) becomes dif-
ficult and often ineffective. This novel and improved 
understanding of pain aetiology requires a paradigm 
shift in pain management of chronic pancreatitis. 
Modern mechanism based pain treatments taking into 
account altered pain processing are likely to increas-
ingly replace invasive therapies targeting the nocicep-
tive source, which should be reserved for special and 
carefully selected cases. In this review, we offer an 
overview of the current available pharmacological op-
tions for pain management in chronic pancreatitis. 
In addition, future options for pain management are 
discussed with special emphasis on personalized pain 
medicine and multidisciplinarity.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Pharmacological pain management in chronic 
pancreatitis is complicated and requires a multidisci-
plinary approach. Identification of risk factors associ-
ated with disease progression and evaluation of extra 
pancreatic causes of pain and complications is essential 
in all patients. Analgesics are typically titrated accord-
ing to the World Health Organization ladder principle, 
but in some situations a top-down approach may be 
useful to control pain and avoid sensitization of central 
pain pathways. Adjuvant analgesics and combinations 
of drugs should be considered at an early stage. Non-
encapsulated enzyme therapy, somastotatin-analogues 
and antioxidants can be considered as supplements to 
conventional analgesics in special situations.
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INTRODUCTION
Chronic pancreatitis (CP) remains a major source of  
morbidity in the Northern Europe, with an annual inci-
dence of  approximately 10/100000 inhabitants[1]. It is a 
disease characterised by progressive destruction of  the 
pancreatic gland and is typically characterised by severe 
abdominal pain. As the disease evolves, significant im-
pairment of  exocrine as well as endocrine functions also 
become evident[2,3]. The aetiological risk-factors associ-
ated with CP are multiple and involve both genetic and 
environmental factors. In the Northern Europe, excessive 
alcohol consumption is the leading cause of  CP, although 
genetic susceptibility is also recognised as playing an in-
creasing role[1,4]. 
From the perspective of  the patients (and their doc-
tors) pain is the most significant symptom in CP, and 
most patients develop chronic pain during the course of  
their disease. The classic description of  the pain is that 
of  a constant, severe, dull ache in the mid-epigastrium, 
which often radiates to the back. It is typically worsened 
by high-fat foods, and pain attacks may last for days. 
However, just as the disease has different causes and 
morphological expressions, this classic pain pattern is not 
universal, and the location, character and quality of  pain 
can be quite variable[2]. Furthermore, pain has been asso-
ciated with malnutrition, narcotic addiction, physical and 
emotional disability, and major socioeconomic problems. 
Consequently, the clinical evaluation of  pain is often 
blurred by addiction to alcohol and narcotic analgesics as 
well as by the personality disorders underlying these de-
pendencies[3,5]. In view of  this complex clinical presenta-
tion, it is not surprising that treatment of  pain in patients 
with CP is challenging and often unsuccessful[6]. 
The aim of  this review is to summarise current avail-
able pharmacological therapies for pain in CP. In addi-
tion, future options for pain management are discussed 
with special emphasis on personalized pain medicine and 
multidisciplinarity.
OVERVIEW OF PAIN MECHANISMS IN 
CP
A detailed overview of  the complex pain mechanisms 
underlying pain in CP is beyond the scope of  this re-
view and provided elsewhere in this issue of  the journal. 
It is important to emphasise that none of  the current 
acknowledged theories are mutually exclusive, and it is 
most likely that several pain mechanisms act in concert to 
cause pain in the individual patient. 
Historically, the focus of  pain treatment has been on 
the pancreatic gland as a nociceptive source, based on 
the assumption that pain is generated by local pathology 
within or in close proximity to the pancreas. This mecha-
nistic understanding of  pain, has for many years, been 
the most widely accepted theory regarding the origin of  
pain in CP[7]. However, there is no direct relationship be-
tween the presence of  pancreatic pathology such as duct 
dilation, pancreatic duct stones, pancreatic duct strictures, 
etc. and abdominal pain in CP pain patients[8-11]. Further-
more, the experimental evidence supporting this theory is 
sparse and findings have been conflicting[12].
On the contrary, many current theories of  the patho-
physiology of  CP postulate that in a high number of  
cases, repeated episodes of  inflammation and pancreatic 
injury drive the process within the gland towards ir-
reversible injury and are associated with damage to the 
pancreatic nerves[7,13,14]. Key in this theory is the recogni-
tion that the resulting ongoing and aggressive nociceptive 
input is likely associated with altered function of  the pain 
processing system, particularly at the central level[15-18]. 
An important ultimate outcome of  such aberrant pain 
processing is that once the disease has advanced and the 
pathophysiological processes are firmly established, the 
generation of  pain can become self-perpetuating and in-
dependent of  the initial peripheral nociceptive drive[19,20]. 
Consequently, the management of  pain by traditional 
methods based on nociceptive deafferentation (e.g., sur-
gery and visceral nerve blockade) becomes difficult and 
ineffective[20]. This novel and improved understanding 
of  pain aetiology requires a paradigm shift in pain man-
agement of  CP. Hence, modern mechanism based pain 
treatments taking into account altered pain processing are 
likely to increasingly replace invasive therapies targeting 
the nociceptive source, which should be reserved for spe-
cial and carefully selected cases. 
RISK-FACTOR MODIFICATION AND 
PROPHYLAXIS 
The risk-factors associated with CP can be classified ac-
cording to the MANNHEIM risk-factor classification 
system[4]. In this system, the multiple (M) risk factors un-
derlying CP are categorised into six major subcategories 
of  alcohol consumption (A), nicotine consumption (N), 
nutritional factors (N), hereditary factors (H), efferent 
pancreatic duct factors (E), immunological factors (I), 
and various rare miscellaneous and metabolic (M) factors. 
The rationale for modifying these risk-factors is to reduce 
recurrent injury to the pancreas. Hence, with repeated 
episodes of  acute inflammation triggered by one or more 
risk factors, the inflammatory environment within the 
pancreas shifts towards chronic inflammation, with sub-
sequent activation of  pancreatic stellate cells, fibrinogen-
esis, and irreversible pancreatic damage[21]. Although not 
well established for all risk-factors (see below), it seems 
likely that prevention of  recurrent pancreatitis attacks, 
clinical or sub-clinical, by risk-factor modification, will 
translate into a slowing of  disease progression, less exo-
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crine and endocrine insufficiency and most importantly 
decreased abdominal pain. In Table 1 recommended risk 
factor modifications are summarized. 
In patients with an alcoholic aetiology of  CP, there is 
evidence to support that cessation of  alcohol may have 
beneficial effects on disease progression and pain[22,23]. 
Furthermore, there is increasing evidence that tobacco 
use is also an important and independent risk factor for 
CP and that cigarette smoking accelerates progression 
of  alcoholic CP[24,25]. Hence, tobacco cessation is highly 
recommended in these patients, although the association 
with pain relief  has yet to be determined. 
Data on the association between nutritional factors 
and CP are sparse. The consumption of  a diet rich in fat 
and protein was associated with the development of  CP 
in a case-control study[26]. However, retrospective descrip-
tions of  daily nutritional habits are difficult and such 
data may be subject to recall bias. Thus, it is difficult to 
provide a simple description of  past daily nutrition in the 
majority of  patients with CP and these findings needs to 
be confirmed in a prospective trial before specific recom-
mendations can be made.
In patients with CP following gallstone pancreatitis, 
prevention of  recurrent choledocholithiasis is crucial 
and reduces further damage to the pancreas[27]. In this 
situation cholecystectomy is recommended for patients 
suitable for surgery[28]. Also, patients with recurrent pan-
creatitis and efferent duct abnormalities such as pancreas 
divisum may benefit from endoscopic therapy or surgery 
to decrease the risk of  recurrent pancreatitis and progres-
sion to CP[29]. However, data on this subject are limited 
and the optimal treatment of  this specific entity is still a 
subject of  controversy. 
No specific treatment exists to modify the disease 
progression in hereditary CP. These patients have a sig-
nificantly increased risk of  pancreatic cancer and surveil-
lance or even total pancreatectomy with autologous islet-
cell transplantation is recommended in some centers[30]. 
Patients with autoimmune pancreatitis comprise a special 
subset of  patients with a potentially curable form of  
pancreatitis. Management of  these patients is beyond the 
scope of  this review and the reader is referred to refer-
ence[31]. 
In CP due to metabolic abnormalities such as hyper-
triglyceridaemia, maintenance of  triglycerides within the 
normal range would be expected to reduce the chance of  
repeated pancreatitis attacks and thus progression to CP[32]. 
Also, patients with hypercalcaemia induced pancreatitis due 
to hyperparathyroidism should be managed appropriately 
and - if  necessary - referred to an endocrinologist. 
TREATMENT OF EXTRA-PANCREATIC 
CAUSES OF PAIN
In addition to risk factor modifications, extra-pancreatic 
causes of  pain should be thoroughly investigated and 
treated (Table 2). Peptic ulcers are reported to have an 
increased prevalence in CP. This is possibly explained by 
changes in blood flow to the mucosa following attacks of  
acute pancreatitis as well as deterioration of  pancreatic 
exocrine function resulting in a reduction of  bicarbonate 
concentration and hence acidification of  the milieu in 
the duodenal lumen. Also, increased gastric acid secre-
tion and an increased prevalence of  Helicobacter pylori in 
CP have been associated with the increased prevalence 
of  peptic ulcers[33]. Another important source of  pain in 
CP is pseudocysts, which should be investigated by an 
appropriate radiological work-up and treated according-
ly[34]. Some patients may have pain as a consequence of  
obstruction of  adjacent viscera (duodenum or common 
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Table 1  Recommended risk factor modifications in chronic pancreatitis according to the MANNHEIM criteria
Risk factor Treatment Comments
Alcohol Alcohol cessation Decrease disease progression and may have beneficial effects on pain
Nicotine Smoking cessation Decrease disease progression and may have beneficial effects on pain
Nutritional No specific recommendations No prospective data
Hereditary Endoscopic surveillance Currently no formal evidence, a prospective trial has been initiated
Pancreatectomy with autolog stem cell transplantation Preferred strategy in some United States centers
Efferent duct Endoscopy or surgical interventions The benefit of intervention is controversial
Immunological Steroid treatment Treatment of autoimmune pancreatitis follows guidelines provided in e.g., Ref. 32
Metabolic Lipid lowering therapy, parathyroidectomy, etc. Consider referral to an endocrinologist
Table 2  Treatment of extrapancreatic causes of pain in chronic pancreatitis
Treatment Comments
Peptic ulcer Proton pump inhibitor +/- eradication of H. pylori Avoid NSAIDs in CP Patients
Pseudocysts Endoscopic drainage, transcutaneous drainage 
or surgical drainage
Preferred treatment dependent on pseudocyst localization 
and morphology
Duodenal obstruction Endoscopic dilation or surgical therapy Endoscopic dilation preferred as first line therapy
Bile duct obstruction Covered metal stent or plastic stent Controversial, one study found no relationship between bile duct 
obstruction and pain
NSAID: Nonsteroidal anti-inflammatory drugs; CP: Chronic pancreatitis; H. pylori: Helicobacter pylori. 
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analgesia[41].
Strong opioids, such as morphine, mainly exert their 
analgesic effects in the central nervous system, although 
it is now well known that opioid receptors are synthe-
sised in the dorsal root ganglia and transported towards 
both central and peripheral nerve terminals[42]. Several 
opioid receptors exist, including the µ-receptor, δ-receptor 
and the κ-receptor[43]. Most clinically available opioids 
have their primary activity at the µ-receptor and have 
been used widely to treat pain in CP patients[6]. How-
ever, animal studies have suggested that activation of  the 
κ-receptor may be more efficacious for attenuation of  
gastrointestinal pain[44]. In keeping with these findings, 
oxycodone (an opioid targeting the µ-, δ- and κ-receptor) 
was shown to attenuate experimental visceral pain better 
than morphine in CP patients[45]. Also, in a pilot study 
including six CP patients with chronic abdominal pain, 
infusion of  a peripherally restricted κ-receptor agonist 
(ADL 10-0101) - but not placebo - reduced clinical and 
experimental pain scores[46]. These findings were not rep-
licated in patients with pain due to pancreatic cancer[47], 
but this may relate to the confounders associated with 
clinical studies on opioids[48]. Taken together, these find-
ings may suggest differentiated effects of  opioids for 
pain management in CP patients. However, it must be 
emphasized that data from well-designed clinical studies 
with long-term follow-up are not yet available. 
Opioids used in the outpatient clinic can be adminis-
tered either orally (i.e., tablets) or transdermally (i.e., patch 
formulation). In an open label randomized crossover 
trial, transdermal fentanyl plaster was compared to sus-
tained release morphine tablets in an equipotent dosage 
regime[49]. No significant differences were found for pain 
control, patients’ preference or quality of  life, while 44% 
of  patients treated with fentanyl plaster reported skin 
side effects. Taken together with the increased costs of  
patch formulation, the authors concluded that transder-
mal administration of  opioids cannot be recommended 
as first line opioid therapy for CP, but should be reserved 
to patients having trouble with tablet ingestion[49]. 
bile duct)[35]. However, the mechanisms underlying such 
“obstructive pain” remain unclear and in the case of  bile 
duct obstruction there is evidence to the contrary[36].
ANALGESICS 
The standard guideline for analgesic therapy in CP pa-
tients follows the principles of  the “pain relief  ladder” 
provided by the World Health Organization (WHO)[37]. 
This principle is based on the serial introduction of  drugs 
with increasing analgesic potency, titrated until pain relief  
is obtained. However, in patients with a severe and de-
bilitating pain pattern, a more aggressive approach using 
opioids combined with adjuvant analgesics as first line 
therapy (i.e., a top-down approach), is useful to control 
pain and prevent sensitization of  central pain pathways. 
An overview of  the current available pharmacological 
therapies used to treat pain in CP is reported in Table 3.
Paracetamol is usually the preferred drug in level I an-
algesia due to its limited side effects. It has analgesic and 
antipyretic activity that work through central and periph-
eral non-opioid mechanisms, which have not yet been 
fully characterised[38]. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) are particular useful for treating mus-
culoskeletal pain and are in general less favourable for 
visceral pain because of  their toxicity to the GI tract[39]. 
Consequently, we recommend avoiding NSAIDs for 
painful CP.
Codeine is a weak opioid in level Ⅱ analgesia, but is 
still associated with the same spectrum of  opioid-related 
side effects seen for stronger opioids, e.g., constipation, 
nausea, dyspepsia amongst other symptoms involved in 
opioid-induced bowel dysfunction[40]. Tramadol possesses 
both a weak opioid agonist activity along with an effect 
on noradrenaline and serotonin uptake in the spinal cord. 
It has been shown to be more potent than codeine and 
may be considered as a halfway house between level Ⅱ 
and level Ⅲ analgesics. Tramadol was also shown to be 
more efficacious than morphine in patients with CP, with 
fewer gastrointestinal side effects for the same level of  
Table 3  Current available pharmacological treatments for pain in chronic pancreatitis
Pain mechanism Treatment option(s) Comments Ref.
Raised levels of CCK Pancreatic enzyme replacement therapy Only non-enteric coated enzymes have proven effective [57-65]
Somatostatin-analogues Conflicting results, prolonged release formulations may be of value [67,68]
Pancreatic inflammation and 
oxidative stress
Antioxidants Conflicting results, probably most valuable in tropical calcifying CP [71,72]
Central sensitisation Antidepressants (TCA, SSRI, SNRI) Expert opinion, no clinical data (Ref.) [2]
Gabapentinoids (Gabapentin/Pregabalin) Modest effect on pain in a randomised placebo controlled trial (Pregabalin) [42]
Ketamine Reverses hyperalgesia in an experimental pain study [54]
Analgesics Tramadol vs morphine No difference in pain relief in a randomised controlled trial, fewer side 
effects on tramadol treatment
[35]
Fentanyl vs Morphine No difference in pain relief in a randomised controlled trial [41]
Oxycodone vs Morphine Oxycodone superior to morphine on experimental pain measures [39]
ADL 10-0101:KOR agonist KOR agonist superior to morphine on experimental and clinical pain 
measures. Limited number of patients (n = 6) 
[40]
CCK: Cholecystokinin; CP: Chronic pancreatitis; TCA: Tricyclic antidepressant; SSRI: Selective serotonin reuptake inhibitor; SNRI: Serotonin 
norepinephrine reuptake inhibitor; KOR: Kappa opioid receptor.
Olesen SS et al . Pain management in chronic pancreatitis
7296 November 14, 2013|Volume 19|Issue 42|WJG|www.wjgnet.com
As discussed above, CP patients may be suffering 
from hyperalgesia due to sensitization of  the central ner-
vous system[14,19]. In general, opioids are not very effective 
in treating established central sensitization and may even 
cause hyperalgesia themselves (i.e., opioid induced hyper-
algesia)[50]. Furthermore, opioid induced bowel dysfunc-
tion is a common problem in clinical practice and typi-
cally manifests as abdominal discomfort or even diffuses 
abdominal pain[40]. Taken together, opioid based therapies 
often become ineffective and associated with gastroin-
testinal side effects in the context of  advanced CP and 
hence other treatments are highly warranted. 
Adjuvant analgesics
Adjuvant analgesics are a heterogeneous group of  drugs 
initially developed for indications other than pain. How-
ever, many have proven effective in painful conditions, 
which has now been widely recognised as a separate 
therapeutic indication. Adjuvant analgesics modify the 
nociceptive processes through several modes of  action, 
including anxiolytic effects (benzodiazepines, alpha-2-
delta ligands), antidepressive effects (antidepressants), 
and anti-hyperalgesic effects (antidepressants, alpha-
2-delta ligands). Although they have been widely used 
to treat pain associated with CP, only the alpha-2-delta 
ligand pregabalin has been studied in the context of  pain-
ful CP[2,51]. Hence, in a placebo controlled double blinded 
randomized trial, we recently demonstrated the efficacy 
of  pregabalin as an adjuvant analgesic for pain in CP. We 
found that CP patients treated with pregabalin escalated 
to a maximal dose of  600 mg bid had a significant reduc-
tion in self-reported pain scores compared to placebo. 
Furthermore, the percentage of  patients with much or 
very much improved health status score was higher in the 
pregabalin group compared to the placebo group. The 
side effects were relatively few and of  mild to moderate 
severity; with a “drunk feeling” being the most prevalent 
side effect (35% of  patients) and typically showing a ceil-
ing effect after one or two weeks of  treatment[51]. 
The analgesic mechanisms of  action underlying pre-
gabalin analgesia are not completely understood, and 
it probably exerts a range of  effects on pain transmis-
sion[52,53]. In vitro studies indicate that pregabalin binds 
selectively to the alpha-2-delta subunit of  voltage-depen-
dent calcium channels, thereby blocking the influx of  
calcium into pre-synaptic nerve terminals. This reduces 
release of  excitatory neurotransmitters, including gluta-
mate, noradrenalin and substance P, and dampens pain 
transmission[54,55]. These findings translate well to experi-
mental pain studies in CP, where antinociceptive effects 
of  pregabalin on electrical evoked pain from the gut and 
skin were observed, compatible with a reduction of  cen-
tral sensitization[56,57].
Ketamine
Introduced in 1965 as an anesthetic, today ketamine is 
used not only for anesthesia, but also as a potent analge-
sic in acute and chronic pain as well as an antihyperalge-
sic used to reduce central sensitization in various chronic 
pain conditions. It is a noncompetitive N-Methyl-D-
aspartate (NMDA) receptor antagonist, but it also exerts 
its analgesic effects through other mechanisms including 
opioid receptor activation[58]. Sensitization of  the central 
nervous system has been documented in several studies 
of  painful CP and is believed to play a prominent role 
in pain generation in this entity[15,16]. One of  the best-
characterized mechanisms in the early phase of  central 
sensitization is activation of  the NMDA receptors[59]. 
Multiple studies have consistently produced positive 
results regarding the use of  ketamine in chronic pain 
patients with central sensitization and hyperalgesia and 
it thus comprises an interesting remedy to revert reduce 
central sensitization and its associated hyperalgesia in 
CP[60]. This was supported by a double-blinded crossover 
trial designed to evaluate the effect of  ketamine infu-
sion on hyperalgesia associated with CP[61]. Infusion of  
ketamine temporarily reversed pressure pain hyperalgesia 
and the underlying sensitized state of  the pain system. 
However, only short-term effects were evaluated and no 
effect was seen on clinical endpoints. Hence, the use of  
ketamine for pain in CP is still in its infancy and prospec-
tive clinical trials are warranted to establish its role in the 
management of  painful CP. 
SUPPLEMENTARY THERAPIES
Pancreatic enzyme therapy 
Pancreatic enzyme therapy for pain control in CP has 
been the subject of  several randomized trials and meta-
analyses (Table 3). The proposed mechanism of  action 
is the ability to degrade cholecystokinin (CCK) releasing 
factor in the duodenum and thereby lower CCK[2]. An 
elevated level of  CCK have been reported in CP patients 
and may generate pain by increasing the pressure in the 
pancreatic duct (CCK-A), but also through direct acti-
vation of  nociceptive pathways in the central nervous 
system (CCK-B)[62,63]. Only non-enteric coated formula-
tions have duodenal protease activity and studies using 
this type of  enzymes have documented improvement in 
pain[64,65]. In contrast, most studies using enteric coated 
preparations (which are not active in the duodenum and 
hence cannot degrade CCK-releasing factor) have not 
shown any improvement on pain measures[66-69]. One 
study, however, showed pain relief  of  enteric coated 
enzymes during acid inhibition, but this study used a 
measurement of  pain that included symptoms of  mal-
absorption (bloating, gas or cramping), rather than more 
traditional pain measures[70]. A meta-analysis combining 
all studies found no effect of  enzymes on pain relief  in 
CP[71]. Nevertheless, combining the two types of  enzyme 
formulations in a metanalysis is probably not appropriate 
given the proposed mechanism of  action[72].
Somastotatin-analogues 
Somastotatin-analogue inhibits pancreatic secretion by 
blocking CCK and secretin release and also by a direct 
Olesen SS et al . Pain management in chronic pancreatitis
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inhibitory effect on acinar cells[73]. As discussed above, 
these effects may alleviate pain through reduction of  pan-
creatic ductal pressure and by lowering the central effects 
of  CCK. There are conflicting data about the efficacy of  
somastotatin-analogues for pain in CP. While early pilot 
series of  octreotide showed an effect on pain control, 
this effect could not be confirmed in a double-blind 
cross-over study enrolling 10 CP patients treated with 
octreotide (100 µg tid) or placebo for 3 d[74]. Although 
pancreatic secretion measured by fecal chymotrypsin was 
reduced by octreotide, no differences were seen in pain 
control or analgesic use. This study has been criticized for 
its relatively short follow-up and limited wash out period 
(48 h). Also, four patients had evidence of  concrements 
in the pancreatic duct, which may have compromised the 
effect of  octreotide. In a later pilot study, a long-acting 
version of  octreotide (Octreotide LAR) administered 
once monthly, was compared to conventional subcutane-
ous octreotide treatment administered three times daily. 
Although not significant, there was a trend toward im-
proved pain control for octreotide LAR[75]. These results, 
however, have never been subject to a formal placebo 
controlled trial and the role of  octreotide treatment for 
painful CP has so far not been satisfactorily documented. 
Taken together with the numerous side effects and their 
cost, a general use of  somastotatin-analogues for pain in 
CP cannot be recommended[76].
Antioxidants
The use of  antioxidants for pain control in CP was pre-
sented two decades ago, but never gained widely clinical 
popularity. The proposed analgesic mechanism of  ac-
tion underlying this therapy is an anti-inflammatory and 
blocking effect on free radicals[77]. Propelled by an Indian 
randomized placebo controlled trial, antioxidant therapy 
recently had a rebirth for pain management in CP. In 
this trial, six months antioxidant therapy was associated 
with significant and prolonged pain relief  compared to 
placebo[78]. However, these findings were not reproduced 
by a subsequent study from North America[79]. A possible 
explanation for this dichotomy may be that the patients 
included in the two trials were different. While the Indian 
study mostly included patients with trophic calcifying 
pancreatitis and malnutrition (and hence deficiency in 
antioxidants), the American study included a more elderly 
population who had alcohol as the leading etiology of  
CP and a normal nutritional condition. Hence, the effi-
cacy of  antioxidant therapy may be related to the etiology 
of  CP and its associated malnutrition[80]. This idea was 
supported by a subgroup analysis of  the patients with al-
cohol etiology in the Indian trial, who, in agreement with 
the American study, demonstrated no benefit of  antioxi-
dants[78]. Taken together, the evidence is not sufficient to 
recommend antioxidant therapy be used routinely for the 
typical Western CP patient with alcoholic pancreatitis.
Other treatments
In addition to the abovementioned treatment options, 
various other pharmacological principles have been used 
to treat pain associated with CP, including leukotriene 
antagonism and stimulation with secretin[81,82]. However, 
none of  these treatments have documented any effect on 
pain and are regarded obsolete by most experts. 
INDIVIDUALISED PAIN THERAPY AND 
FUTURE ANALGESICS FOR PAIN IN 
CHRONIC PANCREATITIS
A major problem in pain medicine is the lack of  knowl-
edge about which treatment suits a specific patient. In a 
recent study, we tested the ability of  quantitative sensory 
testing to predict the analgesic effect of  pregabalin and 
placebo in patients with CP[83]. Pregabalin effect was as-
sociated with pretreatment sensitivity to electric tetanic 
stimulation of  the upper abdominal area (sharing spinal 
segmental innervation with the pancreatic gland). Hence, 
patients expressing lower pain thresholds in the “pan-
creatic viscerotome” were more likely to benefit from 
pregabalin treatment compared to patients with normal 
sensitivity[83]. These findings suggest sensitization of  
spinal neurons in the segment innervated by pancreatic 
visceral afferents to be an important predictor of  prega-
balin efficacy in patients with painful CP. Interestingly, 
this method may be used to tailor pain medication based 
on patient’s individual sensory profile and thus comprises 
a significant step towards personalized pain medicine.
The novel and improved understanding of  pain 
mechanisms in CP may pave the way for new treatments. 
Analgesics specifically targeting neural or humoral me-
diators of  pain, such as nerve growth factor (NGF) and 
transient receptor potential vanilloid-1 antagonists, are 
currently being tested in clinical trials and hold promise 
for the future, although these drugs have yet to be tested 
in patients with CP[84,85]. Recently, a NGF-antagonist 
(Tanezumab) was shown to relief  pain in patients with 
knee pain due to gonarthrosis[84]. As NGF has been 
shown to be up-regulated in CP patients and is known to 
play a pivotal role in the process of  peripheral sensitiza-
tion, NGF-antagonism may be effective for pain relief  in 
CP patients[86]. 
Multidisciplinary pain treatment
As discussed above the mechanisms underlying pain in 
CP are highly variable in the individual patient. Conse-
quently, there is no single approach that is effective for all 
patients and choosing the right algorithm for pain treat-
ment is highly depending of  the pathogenesis of  pain in 
the individual situation. Hence, a successful management 
of  pain requires a multidisciplinary approach as illustrat-
ed in Figure 1. In addition, establishing a stable doctor-
patient relationship is an important factor for a successful 
treatment outcome[80]. 
CONCLUSION
Intense abdominal pain is the most prominent feature of  
CP and its treatment remains a major clinical challenge. 
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Medical management requires a multidisciplinary ap-
proach including identification of  risk factors associated 
with disease progression and appropriate modification. 
A systematically evaluation of  extra pancreatic causes of  
pain and complications followed by appropriate treat-
ments is essential in all patients. Analgesics are typically 
titrated according to the WHO ladder principle, but in 
some situations a top-down approach may be useful 
to control pain and avoid sensitization of  central pain 
pathways. Also, adjuvant analgesics should be considered 
at an early stage and combinations of  drugs are often 
used. Non-encapsulated enzyme therapy, somastotatin-
analogues and antioxidants can be considered as supple-
ments to conventional analgesics in special situations. An 
improved understanding of  pain mechanisms in CP will 
undoubtedly pave the way for new treatments and future 
strategies should be based on modern mechanism based 
and personalized pain treatment.
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